Liquid chromatography–tandem mass spectrometry (LC–MS/MS) reveals distinct sphingolipid patterns in anorexia and obesity.
|Articles|November 6, 2013
- The Column-11-06-2013
- Volume 9
- Issue 20
Market Trends & Analysis Market Profile: Laboratory Information Management Systems (LIMS)
Market Trends & Analysis Market Profile: Laboratory Information Management Systems
Advertisement
Market Trends & Analysis Market Profile: Laboratory Information Management Systems
Articles in this issue
almost 13 years ago
Q&A: Monitoring Microcontaminants in Foodalmost 13 years ago
Honeybee Foragingalmost 13 years ago
Weeding Out Unsafe Drivers: Automating THC Determination in Serumalmost 13 years ago
SFC 2013: Meeting Reviewalmost 13 years ago
Methamphetamine Analogue Found in Dietary Supplementalmost 13 years ago
Environmental NanoparticlesAdvertisement
Related to this article
Leon Niezen and Gert Desmet discuss uncertainty-driven LC method development, peak overlap, and moving from in silico to real data.
Leon Niezen and Gert Desmet describe how predictive uncertainty can make automated LC method development more reliable.
Liquid chromatography–mass spectrometry (LC–MS) serum profiling ties lysine compounds to lupus kidney disease.
Liquid chromatography-mass spectrometry (LC–MS) growth lifts Waters Q3; MOBILion ion mobility buy expands proteomics.
Liquid chromatography–tandem mass spectrometry (LC–MS/MS) measures galactose-1-phosphate in dried blood spots to monitor galactosemia.
Sam Whitmarsh explores how retention-time models handle interlaboratory data, novel chemotypes, unusual phases and ionisable compounds, and what labs need to do to build useful in-house models.
Advertisement
Advertisement
Trending on LCGC International
1
AI/ML Now: Toxicity Prediction for Unknown LC–HRMS Features Using Machine Learning
2
LCGC Blog: Building a Career Series That Goes Beyond the Surface
3
Industry Roundup: Waters Posts Strong Third Quarter as LC–MS and Chromatography Consumables Drive Growth, Acquires Ion Mobility Pioneer MOBILion
4
From 9000 Clues to a Clinical Test: Mass Spectrometry-Driven Lipidomics for Early Cancer Detection
5